Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.

Abstract

Dehydroevodiamine has been reported to have anticholinesterase activity and an anti-amnesic effect. This study examined the effects of dehydroevodiamine on scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia in mice, using a step-through passive avoidance test. Similarly to the cholinesterase inhibitor, physostigmine (0.03--0.3 mg/kg, i.p.), dehydroevodiamine (0.75--12.0 mg/kg, i.p.) administered 30 min before the training trial, immediately after the training trial, and 30 min before the retention test significantly improved scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia. In beta-amyloid peptide-(25--35)-induced amnesia, the rank order of anti-amnesic potency in these three administration schedules for dehydroevodiamine was different from that for physostigmine. Furthermore, dehydroevodiamine was more potent to improve beta-amyloid peptide-(25--35)-induced amnesia than scopolamine-induced amnesia when administered before the training trial. These results suggested that dehydroevodiamine may have an action other than that of an anticholinesterase and may be a novel and effective ligand for improvement of beta-amyloid type amnesia.

• Authors: H H Wang, C J Chou, J F Liao, C F Chen
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 413 Issue 2-3 Pg. 221-5 (Feb 16 2001) ISSN: 0014-2999 [Print] Netherlands
• PMID: 11226396 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Alkaloids
• Amyloid beta-Peptides
• Cholinesterase Inhibitors
• Muscarinic Antagonists
• Peptide Fragments
• amyloid beta-protein (25-35)
• dehydroevodiamine
• Physostigmine
• Scopolamine

Topics

• Alkaloids (administration & dosage)
• Alzheimer Disease (drug therapy)
• Amnesia (chemically induced, drug therapy)
• Amyloid beta-Peptides (adverse effects)
• Animals
• Avoidance Learning (drug effects, physiology)
• Cholinesterase Inhibitors (administration & dosage)
• Male
• Mice
• Mice, Inbred ICR
• Muscarinic Antagonists (adverse effects)
• Peptide Fragments (adverse effects)
• Physostigmine (administration & dosage)
• Scopolamine (adverse effects)